Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC 0142-0000-0002 · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| NNC 0142-0000-0002 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| NNC 0142-0000-0002 | DRUG | A single dose administered subcutaneously (s.c., under the skin) |
| Placebo | DRUG | A single dose administered subcutaneously (s.c., under the skin) |
Inclusion Criteria: * Subjects with CD for at least 3 months * Subjects not treated before, or subjects who have either not responded to treatment, or responded and then lost the response during continued administration of a therapeutic compound Exclusion Criteria: * Any of the following: Symptom...
NNC 0142-0000-0002 is an investigational small molecule being developed for inflammation, specifically studied in moderately to severely active Crohn's disease. It is in Phase 2 clinical development and is not yet approved by regulatory authorities.
NNC 0142-0000-0002 is being developed by Johnson & Johnson, a company traded on the New York Stock Exchange under the ticker JNJ. The drug is currently in Phase 2 clinical trials for inflammation and Crohn's disease.
NNC 0142-0000-0002 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied for safety and efficacy in patients with moderately to severely active Crohn's disease.
NNC 0142-0000-0002 has one completed Phase 2 clinical trial, identified as NCT01203631. This trial evaluated the safety and efficacy of the drug in subjects with moderately to severely active Crohn's disease, enrolling 78 participants across multiple countries including the United States, Belgium, Canada, France, Hungary, Israel, Poland, and Russia.
No alternative names for NNC 0142-0000-0002 have been reported. The drug is identified by this specific code in clinical trial records and is being developed by Johnson & Johnson for inflammation and Crohn's disease.